Noven Pharmaceuticals Inc. (NOVN) is in the Pharma Industry

• Sort by
• View by Content Type
• View Related Content by Tag

• Time to Invest in Pharmaceuticals?

  Howard Sun submits: The prices of many pharmaceutical companies have been beaten down by Wall Street in recent months. With companies like Pfizer PFE, Schering-Plough SGP and Bristol-Myers Squibb BMY reaching lower lows, one has to wonder when the pain will end as these companies are now significantly undervalued. The...

  External links 2008-08-17

  Tags: Healthcare, AstraZeneca Plc., Bristol-Myers Squibb Co., Forest Laboratories Inc., GlaxoSmithKline Plc., Eli Lilly & Co., Merck & Co. Inc., Noven Pharmaceuticals Inc., Novartis AG, Pfizer Inc., Schering-Plough Corp., Sanofi-Aventis, Wyeth

• Amgen Shares Soar on Bone Drug; Questions Remain

  By Lewis Krauskopf NEW YORK (Reuters) - Wall Street is confident Amgen Inc AMGN will win approval for its lead experimental medicine, the osteoporosis drug denosumab, but questions remain about the drug's sales potential. Shares of Amgen, which have been beaten down over...

  News items 2008-07-28

  Tags: Amgen Inc., Analyst, Biotechnology, Investment, Security, Finance, Noven Pharmaceuticals Inc.

• Sanofi to Buy Vaccine Maker Acambis

  By Ben Hirschler LONDON (Reuters UK) - Sanofi-Aventis SASY agreed on Friday to buy vaccine maker Acambis ACM for 276 million pounds, in a deal highlighting big drug companies' hunger for biotech assets. The acquisition of Acambis -- a long-term partner on several projects --...

  News items 2008-07-25

  Tags: GlaxoSmithKline Plc., Genentech Inc., Aecom Technology Corp., Biotechnology, Sanofi Pasteur, Vaccine, Acambis, Noven Pharmaceuticals Inc., Rogers Corp.

• Noven Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript

  Noven Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript

  Earnings calls 2008-05-30

  Tags: Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance, Noven Pharmaceuticals Inc.

• Noven Pharmaceuticals Q4 2007 Earnings Call Transcript

  Noven Pharmaceuticals Q4 2007 Earnings Call Transcript

  Earnings calls 2008-04-14

  Tags: Noven Pharmaceuticals Inc., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

Additional Resources

• Noven Announces 2008 Second Quarter Financial Results

  Noven Reports Quarterly EPS of $0.18, Adjusted EPS of $0.23 Quarterly Net Income at Novogyne Joint Venture Increases 34% to $25.4 Million MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced financial results for the second quarter and first half of 2008. Noven reported net income of...

  Articles 2008-08-06

• Noven Announces Triggering of $25 Million Daytrana® Sales Milestone

  MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced that it has been advised by Shire Limited that Shire's net sales of Daytrana([R]) methylphenidate transdermal system have triggered the third and final $25 million sales milestone due to be paid to Noven. Daytrana([R]), licensed globally to Shire, was...

  Articles 2008-08-04

• Noven Announces 2008 Second Quarter Earnings Release Date

  MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced its 2008 second quarter earnings release date. On August 6, 2008, before the U.S. market opens, Noven is scheduled to issue a press release announcing its financial results for the second quarter and first half of 2008. At 11:00 a.m....

  Articles 2008-08-01

• Noven Announces Final FDA Approval of Stavzor™ for the Treatment of Bipolar Disorder, Seizures and Migraine Headaches

  New Delayed Release Valproate Therapy in Small, Easy-to-Swallow Soft Gel Capsule to be Available in August 2008 MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that the U.S. Food and Drug Administration FDA has approved Stavzor[TM] valproic acid delayed release capsules in 125 mg, 250 mg and 500...

  Articles 2008-07-30

• Banner Pharmacaps Receives FDA Approval for Valproic Acid Delayed Release Softgel Capsules

  HIGH POINT, N.C. -- Banner Pharmacaps Inc., a leader in the pharmaceutical industry for the development of soft gelatin dosage form technology, today announced that the US Food & Drug Administration FDA has granted final approval for the Company's New Drug Application NDA for Valproic Acid Delayed Release soft gelatin...

  Articles 2008-07-30

• Learn about the World Lithium Market

  Reportlinker.com announces that a new market research report related to the Chemicals industry industry is available in its catalogue. World Lithium Market http://www.reportlinker.com/p090606/World-Lithium-Market.html This report analyzes the worldwide markets for Lithium in Metric Tons. The specific end-use segments discussed are Glass & Ceramic, Aluminum...

  Articles 2008-07-07

• Noven Names Anthony Venditti Vice President - Marketing & Sales

  MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced the appointment of senior pharmaceutical executive Anthony Venditti as its Vice President - Marketing & Sales, effective immediately. In this role, Venditti will lead all aspects of the marketing and sales functions at Noven Therapeutics (the company's specialty pharmaceutical...

  Articles 2008-06-30

• The 2008 Dental Industry Metrics Report Out Now

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/bf14ed/2008_dental_indust) has announced the addition of the "2008 Dental Industry Metrics Report" report to their offering. This 476 page report allows any dental industry company to benchmark its performance against both large and small public companies. This year's report...

  Articles 2008-06-26

• Noven Added to NASDAQ NeuroInsights Neurotech Index

  MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) announced today that it has been added to the NASDAQ([R]) NeuroInsights([R]) Neurotech Index (NASDAQ:NERV). The Neurotech Index is designed to track the performance of leading neurotechnology companies listed and actively traded on one of the three major U.S. stock exchanges. ...

  Articles 2008-06-25

• Noven Names Steven M. Dinh Vice President and Chief Scientific Officer

  MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced the appointment of Steven M. Dinh to the newly created position of Vice President and Chief Scientific Officer. In this role, Dinh will be responsible for the functioning, expansion and productivity of Noven's transdermal drug delivery program and related...

  Articles 2008-06-09

• Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA™ Patches Announced

  PHILADELPHIA, June 9 /PRNewswire-FirstCall/ -- Shire Limited , the global specialty biopharmaceutical company, announced today a voluntary recall of two (2) lots of the ADHD patch DAYTRANA (lots 2750211 and 2764111). Shire is taking this action because some DAYTRANA patches do not meet their release liner...

  Articles 2008-06-09

• Noven Provides Update on Daytrana™ Methylphenidate Transdermal System

  Product Licensee Shire Undertakes Voluntary Recall of a Limited Portion of Daytrana[TM] Product MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today provided an update on the status of Daytrana[TM], the only transdermal patch indicated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder ADHD....

  Articles 2008-06-09

• Noven Announces Results of 2008 Annual Meeting of Stockholders

  MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced the results of its 2008 Annual Meeting of Stockholders. At the meeting held earlier today, stockholders elected the following persons to Noven's Board of Directors: * Sidney Braginsky - President and Chief Executive Officer, Atropos Technology Inc.;...

  Articles 2008-06-05

• Noven to Webcast 2008 Annual Meeting of Stockholders

  MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that it will webcast its 2008 Annual Meeting of Stockholders, scheduled for June 5, 2008, at 11:00 a.m. Eastern Time. The live webcast will be available at www.noven.com, and thereafter a webcast replay will be accessible at the same site for at...

  Articles 2008-06-02

• Noven Pharmaceuticals.(Players)

  Noven Pharmaceuticals (Nasdaq-NOVN) has named Peter C. Brandt president and CEO. Brandt, who was a Pfizer executive, DePaul succeeds interim CEO Jeffrey F. Eisenberg, who will remain executive vice president. You can reach Sharon Harvey Rosenberg at rosenbergtrend@yahoo.com

  Articles 2008-06-01